接受伊马替尼治疗的慢性髓性白血病儿童的生长减速。
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia.
出版信息
Eur J Cancer. 2014 Dec;50(18):3206-11. doi: 10.1016/j.ejca.2014.10.007.
PURPOSE
The aim is to study statural growth in a large cohort of children with chronic myeloid leukaemia (CML) treated with front-line imatinib.
METHODS
Retrospective data from 81 children less than 18 years of age with CML identified in the French pediatric registry were analysed. Height was expressed as standard deviation score (SDS).
RESULTS
A gradual decrease in height SDS was observed over time since starting imatinib. The height SDS was significantly lower 12 months and 24 months after the start of imatinib overall (p < 10(-4)) irrespective of gender and pubertal age. The height SDS was significantly (p < 10(-4)) lower 12 months after the start of imatinib in boys and girls, and in the prepubertal age group as well as in the postpubertal age group, respectively. A similar finding was observed in the subgroups of boys and girls starting imatinib at a prepubertal or postpubertal age. Loss in height SDS 12 months after the start of imatinib was of the same range in boys when compared to girls and in patients who started imatinib at a prepubertal age compared to those who started at a postpubertal age.
CONCLUSION
Growth velocity was altered during the first years of imatinib treatment in boys as well as in girls and in prepubertal age patients as well as in adolescents.
目的
研究接受一线伊马替尼治疗的慢性髓性白血病（CML）患儿的身高生长情况。
方法
分析法国儿科注册中心确定的 81 名年龄小于 18 岁的 CML 患儿的回顾性数据。身高用标准差评分（SDS）表示。
结果
自开始使用伊马替尼以来，身高 SDS 随时间逐渐下降。总体而言，无论性别和青春期年龄如何，伊马替尼开始后 12 个月和 24 个月的身高 SDS 显著降低（p<10(-4)）。伊马替尼开始后 12 个月，男孩和女孩的身高 SDS 明显（p<10(-4)）降低，在青春期前和青春期后组中也是如此。在青春期前和青春期后开始伊马替尼的男孩和女孩亚组中也观察到了类似的发现。与女孩相比，男孩在伊马替尼开始后 12 个月时身高 SDS 的降低幅度相同，与青春期后开始伊马替尼的患者相比，青春期前开始伊马替尼的患者也有相同的身高 SDS 降低幅度。
结论
在男孩、女孩、青春期前和青春期患者中，伊马替尼治疗的最初几年期间，生长速度发生了改变。
Zotero 插件